R&D News | pharmaphorum

News

Lilly asks FDA for emergency clearance for COVID-19 antibody...

Eli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing new efficacy data from an ongoing trial.

News

CRISPR pioneers Doudna and Charpentier claim Nobel chemistry...

Drs Emmanuelle Charpentier and Jennifer Doudna have won this year’s Nobel Prize for chemistry in recognition of their work on the gene-editing technology CRISPR/Cas9.

News

GSK and Vir expand COVID-19 antibody trial after Trump's tre...

GlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting heat on Regeneron’s rival that has been famously used to treat pre

News

Close Up Of Senior Man Suffering With Parkinsons Diesease

Axovant pushes on with Parkinson's gene therapy, despite inv...

Axovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from a small cohort of patients from a phase 2 trial.

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Race for COVID-19 vaccine hots up as EMA begins review of Bi...

The European Medicines Agency has begun a second “rolling review” of a potential coronavirus vaccine jointly developed by BioNTech and Pfizer, setting up a race with a rival from AstraZenec

News

BMS bulks up in cardio with $13.1bn takeover deal for MyoKar...

Bristol-Myers Squibb has said it will buy biotech MyoKardia in a $13.1 billion takeover that marks a step up in its development of cardiovascular drugs.

Lilly asks FDA for emergency clearance for COVID-19 antibody...

CRISPR pioneers Doudna and Charpentier claim Nobel chemistry...

GSK and Vir expand COVID-19 antibody trial after Trump's tre...

Axovant pushes on with Parkinson's gene therapy, despite inv...

Race for COVID-19 vaccine hots up as EMA begins review of Bi...

BMS bulks up in cardio with $13.1bn takeover deal for MyoKar...

Hengrui gets world-first okay for platelet drug hetrombopag

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks